Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLLISION RELAPSE trial
NL-OMON54123Phase 3Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Apr 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine, oxaliplatin, fluorouracil, irinotecan and bevacizumab in colorectal cancer liver metastasis (CRLM) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Vrije University Medical Center. Primary endpoint: Overall survival. Started Apr 2023; status: recruiting.
02
Drugs
capecitabineoxaliplatinfluorouracilirinotecanbevacizumab
03
Conditions
colorectal cancer liver metastasis (CRLM)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON54123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54123.